We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,200+ 116,000+ 125M+

Open access books available International authors and editors Downloads

Our authors are among the

151 Top 1% 12.2%

Countries delivered to most cited scientists Contributors from top 500 universities

Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

## Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com

## Meet the editors

Yuan-Chuan Chen completed his PhD in Biochemistry at the University of California, Berkeley, USA, in 2015. His research interests include pharmacy/pharmacology, biochemistry, microbiology/virology, cell/molecule biology, biotechnology/nanotechnology, cell/gene therapy, and policy/regulation. His studies focus on the discovery, application, perspectives, and challenges of biopharmaceuticals. Additionally, he is interested in basic

research, multiple applications, and human therapeutics using CRISPR/Cas9.

Shiu-Jau Chen obtained his medical doctor (MD) degree and completed his PhD in Anatomy and Cell Biology at the National Taiwan University in 1994 and 2013, respectively. His specialty is neurosurgery and brain disease treatment. His studies focus on the prevention and treatment of drug addiction and neurodegenerative diseases. He is also interested in the treatment of Parkinson's disease and Alzheimer's disease using CRISPR/Cas9.

Contents

**Section 1**

**Section 2**

Sperm

**Section 3**

*by Yuan-Chuan Chen*

**Preface III**

Background **1**

**Chapter 1 3**

Animal Research **15**

**Chapter 2 17**

**Chapter 3 41**

Genetically Modified Organism (GMO) **77**

**Chapter 4 79**

Application and Development of CRISPR/Cas9 Technology in Pig Research

Possible Production of Genome-Edited Animals Using Gene-Engineered

Molecular Identification of Genetically Modified Crops for Biosafety and

*by Shahid Nazir, Muhammad Zaffar Iqbal and Sajid-ur-Rahman*

Introductory Chapter: Gene Editing Technologies and Applications

*by Huafeng Lin, Qiudi Deng, Lili Li and Lei Shi*

*by Masahiro Sato and Shingo Nakamura*

Legitimacy of Transgenes

## Contents


Preface

For conventional genetic cloning, target genes are cleaved at restriction sites using restriction endonucleases. Researchers cannot modify genomic sites and it usually takes a lot of work, time, and patience to make and screen for desired clones. Current gene-editing technologies, including ZFNs, TALENs, and CRISPRs/ Cas9, can be utilized to engineer the genes of interest in living organisms with unprecedented efficiency and precision, without the limitation of restriction site availability. Specific and efficient genomic engineering has been performed in human cells, microbes, plants, animals, etc. at will. Additionally, it has been applied in manufacturing products, including testing tools, agricultural products, foods, industrial products, medicinal products, etc. Among them, novel therapeutic strategies based on gene-editing technologies are expected to bring hope for patient recovery from serious diseases for which there are still no effective drugs or medical

Many biotechnology companies have successfully produced nonhuman therapeutic products and medicinal products using gene-editing technologies. More and more products are being developed and approved for sale. Consequently, many enterprises are encouraged to become involved in manufacturing products based on these technologies because of their perspectives for multiple applications. For example, CRISPR has become an industry that is developing prosperously. These enterprises also promote industry innovation through the transfer of technologies

Gene-editing technologies are still being discovered and are expected to become more mature, specific, efficient, and secure for applications in the near future. The potential benefits of these revolutionary technologies are endless. However, like any powerful tool, there are also associated challenges, including safety and ethical/moral concerns, that need to be considered. Research and ethical guidelines from national and international organizations will be critical for funding agencies and institutional review boards to regulate these technologies, especially in the gene editing of human germ line cells and embryos. The aim is to maximize the benefits and minimize the possible risks of gene-editing

We wish all current and future research work, including the discovery, applications, perspectives, and challenges of gene-editing technologies, to have a worthwhile impact on the betterment of human health. It is hoped that all perspectives will become realities and any challenges will be overcome provided that academia, industry, governments, and international societies constantly endeavor and cooperate with each other. Finally, we are grateful for all authors'

and collaboration between academia and industry.

devices available.

technologies.
